Picture Swiss Biotech Association Swiss Biotech Days 2025 SBD25 Basel 650x100px

Document › Details

Aimmune Therapeutics, Inc.. (2/28/19). "Press Release: Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights". Brisbane, CA.

	Organisation	Aimmune Therapeutics Inc. (Nasdaq: AIMT)
	Group	Nestlé (Group)
	Organisation 2	Nestlé Health Science S.A.
	Group	Nestlé (Group)
	Person	Dallas, Jayson (Aimmune Therapeutics 201806– CEO before Ultragenyx + Roche + Novartis + Pfizer + P&G Pharma)

Original document
accessed by [iito] on 2019-03-27

Record changed: 2023-06-05

Picture Swiss Biotech Association Swiss Biotech Days 2025 SBD25 Basel 650x200px

More documents for Nestlé (Group)

[1] Seres Therapeutics, Inc.. (6/6/24). "Press Release: Seres Therapeutics Enters into Memorandum of Understanding for Vowst Asset Sale to Nestlé Health Science". Cambridge, MA....
[2] Recipharm AB. (11/21/23). "Press Release: Marc Funk to Transition to Recipharm's Board of Directors; Greg Behar Appointed New CEO; Inhaled Business to Standalone in 2024"....
[3] Seres Therapeutics, Inc.. (4/26/23). "Press Release: Seres Therapeutics and Nestlé Health Science Announce FDA Approval of Vowst (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial...
[4] Enterome S.A.. (7/18/22). "Press Release: Enterome Signs Major Strategic R&D Collaboration with Nestlé Health Science to Develop and Commercialize New AllerMimics and EndoMimics Immunotherapies for Food Allergies and Inflammatory Bowel Disease". Paris....
[5] Seres Therapeutics, Inc.. (7/1/21). "Press Release: Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement". Cambridge, MA & Lausanne....
[6] ECBF Management GmbH. (12/15/20). "Press Release: The European Circular Bioeconomy Fund Welcomes Nestlé as an Investor to Accelerate Sustainable Innovation in Europe". Luxembourg....
[7] Aimmune Therapeutics, Inc.. (8/31/20). "Press Release: Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science". Brisbane, CA....
[8] Seres Therapeutics, Inc.. (8/17/20). "Press Release: Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock". Cambridge, MA....
[9] Aimmune Therapeutics, Inc.. (2/5/20). "Press Release: Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science". Brisbane, CA....
[10] Aimmune Therapeutics, Inc.. (3/25/19). "Press Release: European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint. Company Intends to Submit European MAA in Mid-2019". Brisbane, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]